Surrozen (NASDAQ:SRZN) Trading Down 3.6% – What’s Next?

Surrozen, Inc. (NASDAQ:SRZN)’s share price traded down 3.6% on Monday . The company traded as low as $11.21 and last traded at $12.00. 146,213 shares were traded during trading, an increase of 553% from the average session volume of 22,375 shares. The stock had previously closed at $12.45.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Guggenheim raised shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price objective for the company in a research report on Friday, January 3rd. HC Wainwright started coverage on shares of Surrozen in a research report on Thursday, January 30th. They set a “buy” rating and a $32.00 target price on the stock.

Surrozen Price Performance

The stock has a fifty day simple moving average of $11.43 and a two-hundred day simple moving average of $10.92.

Institutional Investors Weigh In On Surrozen

Several institutional investors have recently made changes to their positions in the stock. Stempoint Capital LP increased its position in shares of Surrozen by 91.7% in the fourth quarter. Stempoint Capital LP now owns 350,573 shares of the company’s stock valued at $5,031,000 after buying an additional 167,655 shares in the last quarter. Nantahala Capital Management LLC grew its stake in Surrozen by 4.7% during the 4th quarter. Nantahala Capital Management LLC now owns 196,023 shares of the company’s stock valued at $2,813,000 after purchasing an additional 8,817 shares in the last quarter. Stonepine Capital Management LLC lifted its position in shares of Surrozen by 24.7% during the fourth quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock worth $1,969,000 after purchasing an additional 27,200 shares during the last quarter. Regents of The University of California acquired a new stake in shares of Surrozen during the 4th quarter valued at approximately $1,912,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Surrozen during the fourth quarter worth $928,000. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.